Bessemer Group Inc. Lowers Stock Position in Elevance Health, Inc. $ELV

Bessemer Group Inc. lowered its position in shares of Elevance Health, Inc. (NYSE:ELV) by 2.8% in the 4th quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The firm owned 143,194 shares of the company’s stock after selling 4,178 shares during the quarter. Bessemer Group Inc.’s holdings in Elevance Health were worth $50,196,000 at the end of the most recent quarter.

Several other institutional investors and hedge funds have also added to or reduced their stakes in the company. Cornerstone Wealth Management LLC purchased a new position in Elevance Health during the fourth quarter valued at $328,000. Plancorp LLC lifted its position in Elevance Health by 13.3% during the fourth quarter. Plancorp LLC now owns 1,831 shares of the company’s stock valued at $642,000 after buying an additional 215 shares during the period. Western Wealth Management LLC lifted its position in Elevance Health by 31.4% during the fourth quarter. Western Wealth Management LLC now owns 1,222 shares of the company’s stock valued at $428,000 after buying an additional 292 shares during the period. Atlas Private Wealth Advisors purchased a new position in Elevance Health during the fourth quarter valued at $208,000. Finally, Navalign LLC purchased a new position in Elevance Health during the fourth quarter valued at $45,000. Hedge funds and other institutional investors own 89.24% of the company’s stock.

Wall Street Analysts Forecast Growth

Several brokerages have commented on ELV. Mizuho lowered their price objective on Elevance Health from $413.00 to $350.00 and set an “outperform” rating for the company in a research report on Wednesday, March 11th. Guggenheim raised their price target on Elevance Health from $396.00 to $399.00 and gave the company a “buy” rating in a report on Friday, April 24th. Deutsche Bank Aktiengesellschaft raised their price target on Elevance Health from $332.00 to $363.00 and gave the company a “hold” rating in a report on Thursday, April 23rd. Citigroup upgraded Elevance Health to a “buy” rating in a report on Wednesday, April 29th. Finally, JPMorgan Chase & Co. raised their price target on Elevance Health from $397.00 to $411.00 and gave the company an “overweight” rating in a report on Tuesday, April 28th. Thirteen equities research analysts have rated the stock with a Buy rating and ten have given a Hold rating to the stock. Based on data from MarketBeat.com, Elevance Health presently has an average rating of “Moderate Buy” and an average target price of $384.58.

Elevance Health Price Performance

Shares of NYSE:ELV opened at $392.74 on Friday. Elevance Health, Inc. has a 1-year low of $273.71 and a 1-year high of $412.96. The company has a debt-to-equity ratio of 0.70, a current ratio of 1.48 and a quick ratio of 1.48. The business has a fifty day moving average price of $322.88 and a 200-day moving average price of $334.02. The company has a market capitalization of $85.29 billion, a PE ratio of 16.71, a PEG ratio of 2.26 and a beta of 0.66.

Elevance Health (NYSE:ELV) last released its quarterly earnings data on Wednesday, April 22nd. The company reported $12.58 EPS for the quarter, topping the consensus estimate of $10.74 by $1.84. Elevance Health had a return on equity of 15.58% and a net margin of 2.62%.The company had revenue of $49.49 billion during the quarter, compared to the consensus estimate of $48.21 billion. During the same period last year, the company earned $11.97 EPS. Elevance Health’s revenue for the quarter was up 1.5% on a year-over-year basis. Elevance Health has set its FY 2026 guidance at 19.850- EPS. As a group, equities analysts expect that Elevance Health, Inc. will post 26.79 EPS for the current fiscal year.

Elevance Health Dividend Announcement

The firm also recently disclosed a quarterly dividend, which will be paid on Thursday, June 25th. Investors of record on Wednesday, June 10th will be issued a $1.72 dividend. This represents a $6.88 annualized dividend and a yield of 1.8%. The ex-dividend date is Wednesday, June 10th. Elevance Health’s dividend payout ratio (DPR) is presently 29.26%.

Elevance Health Profile

Elevance Health, Inc (NYSE: ELV) is a large U.S.-based health benefits company that provides a broad range of health insurance products and related services. Headquartered in Indianapolis, the company rebranded from Anthem, Inc to Elevance Health in 2022 while continuing to operate consumer-facing health plans under established state and national brands. Gail Boudreaux serves as chief executive officer and president, leading the company’s strategic focus on integrated health care and benefit delivery.

Elevance’s core activities include offering medical and specialty health plans for individuals, employers and government programs, including Medicare and Medicaid managed-care products.